Bile Duct Cancer Research from Dana-Farber Cancer Institute
3 意见
• 06/16/23
0
0
嵌入
New treatment options are greatly needed in Bile Duct Cancer (cholangiocarcinoma). New research led by Dana-Farber's James Cleary, MD, PhD in Cancer Discovery finds FGFR2 deletion may predict clinical benefit to molecularly targeted therapy. Video published April 30, 2021.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论